|
|
An FDA-approved monotherapy for 3rd line follicular lymphoma (FL)
4/19/2018 Speaker: Micah Matthew Burch, MD
|
|
|
|
|
|
|
NERLYNX, The Next Step in Early Stage HER2+ Breast Cancer
2/12/2018 Speaker: Jay Andersen, MD, Associate Chair Breast Program, The US Oncology Network, Compass Oncology
|
|
|
|
|
|
|
Recurrent Ovarian Cancer – New Maintenance Therapy
9/12/2017 Speaker: Oliver Dorigo, MD, PhD, Stanford Women’s Cancer Center, Department of Obstetrics and Gynecology
|
|
|
|
|